



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

24 May 2012
EMA/CHMP/273712/2012
Press Office

Organisational matters

CHMP meeting 21-24 May 2012

The main organisational topics addressed during the May 2012 CHMP meeting related to:

- Endorsement for a new three-year term of Dr Jean-Louis Robert as the CHMP representative to the CAT and Dr Guy Berchem as his alternate member in the CAT.
- The adoption of the revised Work Plan 2012 for the Central Nervous System Working Party. The document now additionally lists the 'Clinical investigation of medicinal products in the treatment of Parkinson's disease' guideline (CPMP/EWP/563/1995 Rev. 1) where clarification on inclusion criteria will be added.
- The Scientific Advisory Group on Anti-Infectives and renewal of its mandate for the next 3-year term until May 2015.
- The adoption of the revised 'Procedural advice on CHMP/CAT Rapporteur/Co-Rapporteur appointment principles, objective criteria and methodology in accordance with Article 62 (1) of Regulation (EC) No 726/2004'. The document now includes more detailed criteria for the appointment of Rapporteurs for generic/hybrid medicinal products. For generic medicinal products for which several applications with the same active substance are expected a Peer Reviewer will be introduced; furthermore a small group of Rapporteurs/Peer Reviewers will be identified for generic products with the same active substance in order to ensure and facilitate consistency.
- The adoption of the mandate, objectives and rules of procedure of the EMA pandemic task force (ETF). The group will be convened only during a pandemic and will, under supervision of CHMP, be responsible for providing advice on pandemic vaccine applications/issues. This document will be published when the overall pandemic plan and associated documents are finalised.
- The adoption of the document 'Management of the rapporteur workload during assessment of pandemic vaccines'. This document sets out mechanisms to ensure that there are sufficient resources to perform assessment of pandemic vaccine applications throughout the network during a pandemic. This document will be published when the overall pandemic plan and associated documents are finalised.

